The evolution of durvalumab in NSCLC care
Hospital Pharmacy Europe
NOVEMBER 4, 2024
Durvalumab is ‘promising step forward’ The latest approval from the MHRA is based on positive data from the AEGEAN Phase III trial in rNSCLC , which showed that durvalumab-based treatment before and after surgery reduced the risk of recurrence, progression events or death by 32% versus neoadjuvant chemotherapy alone.
52 
Let's personalize your content